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IgM Antibodies to Apoptosis-Associated Determinants Recruit
C1q and Enhance Dendritic Cell Phagocytosis of Apoptotic Cells1
Yifang Chen, Yong-Beom Park, Ekta Patel, and Gregg J. Silverman2
Natural Abs, which arise without known immune exposure, have been described that specifically recognize cells dying from apoptosis,
but their role in innate immunity remains poorly understood. Herein, we show that the immune response to neoantigenic determinants
on apoptotic thymocytes is dominated by Abs to oxidation-associated Ags, phosphorylcholine (PC), a head group that becomes exposed
during programmed cell death, and malondialdehyde (MDA), a reactive aldehyde degradation product of polyunsaturated lipids pro-
duced following exposure to reactive oxidation species. While natural Abs to apoptotic cells in naive adult mice were dominated by PC
and MDA specificities, the amounts of these Abs were substantially boosted by treatment of mice with apoptotic cells. Moreover, the
relative amounts of PC and MDA Abs was affected by VH gene inheritance. Ab interactions with apoptotic cells also mediated the
recruitment of C1q, which enhanced apoptotic cell phagocytosis by immature dendritic cells. Significantly, IgM Abs to both PC and
MDA were primary factors in determining the efficiency of serum-dependent apoptotic cell phagocytosis. Hence, we demonstrate a
mechanism by which certain natural Abs that recognize neoantigens on apoptotic cells, in naive mice and those induced by immune
exposure to apoptotic cells, can enhance the functional capabilities of immature dendritic cells for phagocytic engulfment of apoptotic
cells. The Journal of Immunology, 2009, 182: 6031–6043.
T he selective and efficient elimination of cell corpses isindispensable for maintaining tissue homeostasis as wellas for the resolution of inflammation and the prevention
of autoimmune disease. However, apoptosis is an obligatory out-
come of development, proliferation, and cell differentiation that
continues throughout life, and every day 1011 cells in our bodies
die by apoptosis. Apoptotic cells (ACs)3 are therefore ubiquitous
and abundant; nonetheless, in health they do not pose an immedi-
ate threat to the host because of innate immune processes that
safely dispose of dying cells. In many settings the professional
phagocytic cells, macrophages, have the primary responsibility for
the clearance of cell corpses. However, if efficiency is limited there
is greater opportunity for cellular progression to secondary necro-
sis and release of proinflammatory factors and autoantigens that
may select pathogenic B and T cell clones.
Dendritic cells (DCs) at early stages of differentiation (i.e., im-
mature DCs) also phagocytose ACs by a process that enables the
constant steady-state sampling and presentation of self-Ags (reviewed
in Ref. 1). In vivo experiments have previously demonstrated that
these interactions with ACs can induce immunologic tolerance (2, 3).
However, DCs also serve as sentinel immune cells, and when induced
to fully mature they lose phagocytic capacity, up-regulate costimula-
tory molecules and chemokine receptors, migrate to draining lymph
nodes, and become potent APCs. Fully activated DCs can also be
high-level producers of a range of cytokines and chemokines. As AC
ingestion is reported to block the induced maturation of DCs (4), the
differentiation status and phagocytic capacity of DCs may be central
determinators of the homeostatic set point for the maintenance of
immunologic tolerance as well as for the integration of pro- and an-
tiinflammatory responses (1).
The in vivo clearance of dying cells is a specialized and com-
plicated multistep process, which has been conserved since early in
evolution, and it involves numerous phagocyte receptors, signaling
transducers, and membrane-associated ligands and soluble bridg-
ing molecules that provide “eat me” signals for phagocytic cells.
Among these signals are recognition molecules, such as comple-
ment factors, collectins, ficolins, C-reactive protein, surfactant pro-
tein A, surfactant protein D, adiponectin, 2-glycoprotein-1, and
galectin, that can be selectively deposited on ACs (reviewed in
Refs. 5, 6). These opsonizing factors appear to have redundant
functions, and their relative dominance may vary depending on
anatomic site and physiologic or pathologic context.
The Ab products of the B cell compartment of the adaptive
immune system can also specifically recognize cells dying from
apoptotic death and distinguish them from healthy cells (7–10).
AC immunization of mice with healthy immune systems has been
reported to induce Abs to ACs due to the recognition of a range of
self-Ags, which include nuclear Ags, cardiolipin, and ssDNA (11).
Other studies have reported that AC immunization induces the
production of Abs, which are reactive with the phosphorylcholine
(PC) headgroup of phosphatidylcholine, that is exposed following
oxidative damage to the polyunsaturated fatty acid side chain in
position 2 of the glycerol backbone, such as the reactive aldehyde
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphatidylcholine
(POVPC) that is generated during apoptosis (7, 10, 12, 13). AC
death can also lead to caspase-3 activation of the calcium-inde-
pendent phospholipase A2 that can remove the fatty acid at the
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sn-2 position of phosphatidylcholine to generate lyso-phosphati-
dylcholine, which is also recognized by PC-specific Abs (9). Im-
portantly, these anti-PC Abs do not bind nonoxidized phosphati-
dylcholine, which explains why they do not interact with healthy
cells. Other oxidation-associated neodeterminants have also been
implicated, such as 4-hydroxy-2-nonenal (4-HNE) and malondial-
dehyde (MDA), which are degradation products of the interactions
of unsaturated lipids with reactive oxidation species (14, 15). In
fact, MDA production is used as a biomarker for the measurement
of oxidative stress (16).
To investigate the potential contributions of Abs to innate immune
functions, we have characterized the AC-specific responses in immu-
nocompetent naive mice and after i.v. challenge. As classical com-
plement pathway factors are known to be recruited to Ab-containing
immune complexes, while some are also directly deposited on ACs,
we therefore assessed whether these anti-AC responses can affect the
recruitment of such soluble opsonic eat me signals. Additionally, we
studied the influence of these factors on phagocytosis by immature
DCs, which may play pivotal roles in the maintanence of peripheral
tolerance. Our findings provide a new perspective on the role of nat-
ural Abs for AC recognition and opsonization, as well as how these
interactions can affect the functional capabilities of DCs.
Materials and Methods
Mice
Age- and gender-matched adult BALB/c or C57BL/6 and congenic B cell-
deficient muMT mice (provided by The Jackson Laboratory), congenic
S107.1/ mice (17) (kind gift of J. J. Kenny and R. Fischer, National
Institutes of Health, National Institute on Aging), and congenic C3/
(kind gift of M. Carroll, Center for Blood Research, Boston, MA) mice
were bred under specific pathogen-free conditions as supervised by the
University of California at San Diego Animal Care Program. All animal
protocols were approved by the University of California at San Diego
Institutional Animal Care and Use Committee.
Apoptotic cell treatment
Based on pilot studies with outcomes assessed after weekly treatments, groups
received i.v. 2.5  107 freshly apoptotic (etoposide-treated) thymocytes (see
below) in PBS by tail vein injection, with bleeds obtained on day 16. Control
studies revealed equivalent results with thymocytes induced to apoptosis by
gamma irradiation, or by incubation with etoposide at 10M (Sigma-Aldrich),
dexamethasone at 1 M (Sigma-Aldrich), or 50 ng/ml PMA (Sigma-Aldrich)
in RPMI 1640/10% FCS for 15 h (not shown). Apoptosis was confirmed based
on annexin V staining, TUNEL staining, nuclear condensation, and cytoplas-
mic bleb formation (not shown).
Antibodies
T15 IgM (from the EO6 hybridoma) (18) and the IgM isotype control from the
hybridoma, NC17-D8 (19) (gift of L. Arnold, University of North Carolina,
Chapel Hill NC), which both express J chain transcripts (data not shown), were
produced under serum-free conditions in hollow-fiber (10,000 MWCO) bio-
reactors in hybridoma serum-free media (Invitrogen) to a cell density of 5–
10 108/ml and then maintained for 30–45 days by the National Cell Culture
Center (Minneapolis, MN). Supernatants were purified with a 300-kDa tan-
gential flow filtration device, followed by a 10-kDa tangential flow filtration
for further concentration, and then dialyzed against PBS (pH 7.2), with doc-
umented low endotoxin (0.5 EU/mg). Aliquots were stored at 80°C. By
native PAGE analysis and Western blot, IgM populations were predominantly
pentamers with 10% hexamers and without monomeric IgM or other low
molecular mass species (data not shown).
Ig immunoassays
Standard sandwich ELISAs were performed with precoats of goat anti-IgM
or anti-IgG (Jackson ImmunoResearch Laboratories), PC-BSA (Biosearch
Technologies), pneumococcal cell wall polysaccharide (C-PS; Statens Se-
rum Institut, Copenhagen Denmark), MDA-BSA (Academy Biomedical),
oxidized low-density lipoprotein (Ox-LDL; gift of J. Witztum, University
of California at San Dieto), or BSA (Sigma-Aldrich) for control Ags, with
detection with anti-IgM or anti-IgG, as described (20).
Ag microarray studies were performed as recently described, with the
same complete Ag ligand panel (21). As described (21), background cor-
rection used a Matlab script, and the mean values for replicate spots were
determined with JMP 7.0 software (www.jmp.com). Cluster analysis dia-
grams from comparisons of replicate arrays, after processing with mono-
clonal IgM or sera, were generated with Cluster 3.0 (Stanford University)
and Java TreeView (rana.lbl.gov/EisenSoftware.htm). Background levels
were confirmed based on replicate slides developed without sera or IgM
(not shown). In these studies, a level of 600 digital fluorescence intensity
units was set as a threshold for significant reactivity, which was the mean
background3 SD. These data have been deposited in the National Center
for Biotechnology Information’s Gene Expression Omnibus (accession no.
GSE14958; www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc).
ELISPOT analyses
ELISPOT analyses were performed as previously described (20), with pre-
coating of membranes at 10 g/ml overnight at 4°C. Mononuclear cell
suspensions from spleen or bone marrow were then added to triplicate
wells for each condition at 400,000, 100,000, 25,000, and 6,250 cells/well.
Final values were calculated per 106 mononuclear cells.
IgG depletion studies
To deplete IgG from serum samples, 200-l aliquots of sera from AC-
treated adult BALB/c mice were equilibrated with a protein G-Sepharose
column (Millipore) for 1 h at room temperature, and the flow-through
sample was then isolated for further analysis. As a control, a serum aliquot
from the same mouse was instead passaged over BSA-Sepharose column
by the same technique. Samples were normalized for IgM content by
ELISA and then used in side-by-side assays, along with an untreated serum
aliquot.
Complement deposition studies
For in vitro complement deposition, apoptotic thymocytes were incubated
at 37°C with IgM at 20 g/ml in TBS alone or TBS with 20% Ig-deficient
plasma for complement/opsonins. After 40 min, cells were washed and
studied for apoptosis (7-aminoactinomycin D and annexin V) and with
allophycocyanin-labeled goat anti-IgM and FITC-labeled rat anti-mouse
C1q (Cedarlane Laboratories) in the presence of Fc block (22).
Phagocytosis studies
With regard to apoptotic clearance assays, and by adapting previously de-
scribed methods, for assays of DC phagocytosis of ACs (4, 23–25), bone
marrow cells from femurs and tibiae were collected by flushing with RPMI
1640 media, and disaggregate cells were passed through a 70-m nylon
cell strainer (BD Falcon) to remove cell clumps. Cells were washed with
RPMI 1640 media and centrifuged at 1200 rpm for 10 min and then re-
suspended and cultured at 1 106/ml with complete RPMI 1640 with 10%
heat-inactivated FBS, 10 mM HEPES, 100 U/ml penicillin plus 100 g/ml
streptomycin, 2 mM glutamine, and 50 M 2-ME, containing GM-CSF 10
ng/ml (eBioscience) and cultured at 37°C with 5% CO2 for 72 h. We then
added 25 ml of fresh complete supplemented RPMI 1640 with 10 ng/ml
GM-CSF for another 48 h. Nonadherent cells were then collected and DCs
selected in the presence of Fc block with magnetic anti-CD11c beads using
LS magnetic columns (Miltenyi Biotec) to 98% CD11c purity, as well
as undetectable B220 staining. These immature conventional DCs were
then washed thrice and used as described below.
To assays for phagocytic activity, isolated thymocytes were labeled with
CFSE stock solution, using a modified manufacturer’s protocol (Molecular
Probes) at a final concentration of 107 cells/ml and a final CFSE concen-
tration of 5 M at room temperature in the dark for 20 min. Cells were then
quenched by the addition of 5 vol of ice-cold complete RPMI 1640 media,
and then cells were washed three times. In most experiments, apoptosis of
thymocytes was induced by incubation at 2  106/ml with complete RPMI
1640 media with etoposide (Sigma-Aldrich) at 10 M in 5% CO2 incu-
bator at 37°C overnight. Before use, apoptotic thymocytes were washed
four times in complete media. Etoposide was preferred due to generally
greater homogeneity by flow cytometry with 92% annexin V (i.e., ap-
optotic) with low levels (25%) of 7-aminoactinomycin D cells.
Equal numbers of DCs and ACs (each at 5  105) were then cultured in
serum-free media (StemSpan SF expansion; StemCell Technologies) for 60
min at 37°C with 5% CO2, or as indicated. In pilot time-course studies,
conditions were determined for optimal discrimination of DC subpopula-
tions (not shown), as previously described (24). To quantitate uptake of
ACs by DCs during data analysis, we first excluded cell fragments and
blebs with a wide mononuclear cell scatter gate (i.e., forward light scatter
vs side light scatter) and then gated on all DCs, based on CD11c-allophy-
cocyanin or MHC II-allophycocyanin staining (BD Biosciences).
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Immunofluorescence studies
For immunofluorescence microscopic studies, cytospins were prepared af-
ter culture with CFSE-labeled thymocytes and stained with allophycocya-
nin rat anti-mouse CD11c (BD Biosciences). In these DC/AC preps, 700
DCs were counted per condition by deconvoluted microscopy by a Delta-
Vision deconvolution instrument with a Nikon TE-200 microscope (20)
with images collected within the linear range of the CoolSNAP camera. To
quantitate these results, microscopic studies determined the percentage of
DCs that had ingested one or more AC or apoptotic fragments that were50%
internalized, and not just associated with the DC membrane (26), by the for-
mula: % DCs  (no. of DCs with engulfed ACs)/(total number of DCs).
Certain assays used purified human C1q (Quidel), which is reported to be
functionally equivalent to murine C1q (25).
Statistical analysis
Values are reported as means  SD unless otherwise stated. Significance
was assigned for p  0.05 by two-tailed t test, with Welsh correction, or
ANOVA, as appropriate (InStat; GraphPad Software).
Results
PC and MDA reactivity dominate Ab responses to ACs
To investigate the binding specificity of natural Abs that recognize
ACs, surveys were performed with an 800-feature proteomic Ag
array that encompassed 100 different Ags and control ligands
(21). These included a broad range of determinants associated with
autoimmune pathogenesis, as well as known targets of natural Abs
and antimicrobial responses (Fig. 1).
As a control, we first tested the reactivity of purified monoclonal
T15 IgM, a natural Ab product of a prototypic clonal set, which is
defined by specific canonical Ab gene usage (27) that resides within
the B-1 cell subset (28). As expected, the T15 natural Ab displayed
strong reactivity with a range of PC-containing Ags that included the
PC-BSA conjugate, the purified pneumococcal C-PS, in which PC is
an immunodominant epitope (29), and the pneumococcal polysaccha-
ride vaccine, Pneumovax. Reiterating past reports, T15 IgM also rec-
ognizes copper oxidized LDL and MDA-modified LDL, in which
both MDA and PC determinants are displayed (18). Hence, these
studies confirm the binding specificity of T15 IgM for exogenous and
endogenous Ags that express PC determinants, while the VH11/V9-
expressing B-1 cell-derived isotype control IgM, NC-17D8 (19), was
nonreactive with all tested Ags.
From autoantigen microarray surveys of sera of adult C57BL/6
(B6) mice, we found that i.v. infusions of apoptotic thymocytes
induced increased levels of circulating IgM that also predomi-
nantly recognized PC-BSA, C-PS, Pneumovax, Ox-LDL, and
MDA-LDL, and with limited reactivity with DNA-containing Ags
(e.g., ssDNA, dsDNA, chromatin, and nucleolar extract) and a few
other Ags (Fig. 1). In contrast, sera from naive and control-treated
(i.e., saline, PBS) mice demonstrated a pattern of only weak reac-
tivity with MDA-LDL, other PC-containing Ags, and DNA-con-
taining Ags (Fig. 1). Hence, AC infusions do not induce nonse-
lective autoantibody responses. Instead, ACs represent potent
immunogens for the induction of IgM Abs that prominently rec-
ognize the oxidation-associated immunodominant phospholipid
neoantigens PC and MDA.
VHS107.1 is needed for efficient recognition of PC, but not
MDA, epitopes on ACs
To better understand the basis for immune recognition of phos-
pholipid-associated neodeterminants on ACs, we compared the Ab
responses of B6 mice with congenic mice that have a targeted
homologous recombination that deletes the inherited germline
VHS107.1 gene segment (B6.S107.1/). The VHS107.1 gene is
known to be required for the generation of T15-related anti-PC
Abs (17). Confirming the above-described microarray findings,
ELISA studies with a PC-BSA conjugate showed that naive B6
mice had substantial levels of IgM anti-PC Abs, while AC immu-
nization induced a mean 40-fold increase (Fig. 2). There was a
comparable induction of the Ab response to PC-containing pneu-
mococcal C-PS. In contrast, naive B6.S107.1/ mice, which can-
not produce T15-related Abs, displayed a profound deficiency in
PC reactivity, demonstrated by greatly diminished responses to
both PC-BSA and C-PS, which were not substantially boosted by
AC treatment (Fig. 2). These findings document that the VHS107.1
gene is required for robust B cell responses to PC determinants on
ACs, in the same way as it is required for immune recognition of
PC determinants on pneumococci (17).
Importantly, in contrast to the differential PC reactivity, both
B6 and B6.S107.1/ mice displayed substantial IgM reactivity
with the MDA-BSA conjugate, and levels in naive mice of both
FIGURE 1. AC treatment induces Abs that predominantly recognize PC
and MDA Ags in multiplex Ag arrays. Binding of IgM is shown with
replicate autoantigen microarrays, with mAbs, T15 IgM, or isotype control
(at concentrations in ng/ml as shown) or adult B6 sera at 1/200, unless
otherwise indicated. Sera were obtained from individual naive age-matched
adult B6 mice or at day 16 from mice that received three infusions of saline
control treatment (PBS A and PBS B), or apoptotic thymocytes on days 0,
7, and 14 (Apoptotic A and Apoptotic B). Results are representative of two
independent experiments.
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strains were significantly increased by AC treatment (Fig. 2). In
fact, mean levels of IgM anti-MDA Abs were significantly
higher in naive B6.S107.1/ (i.e., T15-deficient) mice than in
naive wild-type B6 mice (Fig. 2) ( p  0.005). While both
strains of mice displayed comparable naive and post-AC IgM
responses to the more antigenically complex Ox-LDL, the T15-
deficient B6.S107.1/mice instead showed higher naive ( p 0.03)
and postimmune ( p  0.003) responses than did B6 mice to MDA-
LDL, a form of LDL modified to enhance MDA antigenic expression.
To understand the cellular origins and anatomic distribution of
Ab-producing B cells induced by AC immunization, we performed
ELISPOT analyses on mononuclear cells from spleen and bone
marrow, major sites of natural Ab production (20). As illustrated in
Fig. 3A, a significant proportion of splenic IgM-secreting cells in
naive B6 mice bound to PC Ags (i.e., PC-BSA 3.1  1.7%; C-PS
2.6  0.5%; mean  SD) (Fig. 3C). In naive B6 mice, the levels
of splenic IgM-anti-MDA-secreting cells were significantly higher
(8.29  3.18%) ( p  0.02) than anti-PC responses, while reac-
tivity levels with both types of apoptosis-associated Ags were well
above the observed levels of interaction with the control Ag, un-
modified BSA (0.3  0.2%) (Fig. 3C).
Compared with naive mice (809  192/106 splenocytes), AC
treatment resulted in only modest but significant increases in the
levels of total IgM-secreting cells (1418  175/106 splenocytes,
p  0.003), while there was a great induction in the relative rep-
resentation of anti-PC (PC-BSA 35.9  12.3%, p  0.002; C-PS
14.5 5.9%, p  0.007) and anti-MDA IgM-secreting cells
(23.5  12.2%, p  0.05) (Fig. 3, A and C).
While B6.S107.1/ mice displayed comparable overall lev-
els of splenic IgM-secreting cells, the frequencies of anti-PC
IgM-secreting cells (0.5  0.3% and 0.57  0.2%) in naive
mice were only modestly above the level of reactivity with the
control Ag, BSA (0.3  0.13%) (Fig. 3, B and D), while levels
of MDA-reactive IgM-secreting cells (12.6  5.6%) in naive
B6.S107.1/ mice were comparable to those in naive B6 mice.
After AC treatment, anti-PC levels in B6.S107.1/ mice (PC-
BSA 7.3  4.9%; C-PS 1.6  0.7%) remained significantly
lower than in B6 mice ( p  0.014 and 0.005, respectively).
Importantly, even though anti-PC responses were greatly di-
minished in B6.S107.1/ mice, AC treatment did significantly
increase levels of MDA-reactive IgM-secreting cells in these
T15-deficient mice (44.5  13.7%) strains ( p  0.005) (Fig. 3).
Furthermore, although the overall frequency of total IgM- and
Ag-specific IgM-secreting cells were several fold lower in the
bone marrow than in the spleen (Fig. 3E), the same general
patterns were demonstrated (Fig. 3, C and E). Therefore, these
ELISPOT data reiterate patterns seen in the above-described ELISA
findings; as compared with B6 mice, the B6.S107.1/mice were
confirmed to have a profound defect in the capacity to recognize and
respond to PC determinants on ACs, while anti-MDA responses were
generally unimpaired or even increased.
Although the overall frequencies of induced IgG-secreting
cells were considerably lower than for IgM-secreting cells (Fig.
3, D and F), we found similar patterns in the spleen and bone
marrow, with significantly lower levels of PC-specific IgG-se-
creting cells in the T15-deficient B6.S107.1/ mice than wild-
type mice after AC immunization ( p  0.001). Levels were also
assessed in naive mice, but were too low for meaningful com-
parisons. However, there was a trend in the B6.S107.1/ mice
toward higher AC-induced MDA-specific IgG-secreting cells
compared with B6 mice ( p  0.16) (Fig. 3). Notably, these
induced IgG Ab responses were overwhelmingly of the IgG3
subclass (data not shown), which suggested that akin to T15
responses to pneumococcal immunization (30, 31), i.v. AC in-
fusions without adjuvant also induces T cell-independent type
II responses. Taken together, these findings indicate that im-
mune development in a setting of paucity of VHS107.1-express-
ing B cell precursors leads to anti-AC immune responses with
relative expansion of MDA-reactive B cells.
T15 IgM Ab enhances the recruitment of C1q to ACs
To better understand the potential functional capabilities of anti-
AC Abs, we examined the capacity of these responses to recruit
complement. Earlier reports have shown that direct interactions
of ACs with C1q, the recognition molecule of the classical com-
plement pathway, can play a prominent role in the phagocytic
clearance of ACs (32–35). We found that incubation with sera
from muMT mice (36), which provides a source of soluble op-
sonizing factors devoid of Ig (i.e., Ig-deficient sera), resulted in
the deposition of C1q onto ACs but not healthy cells (Fig. 4A),
which confirmed that C1q can interact with apoptosis-associ-
ated motifs, such as exposed phosphatidylserine residues (37,
38). Importantly, the addition of purified T15 IgM Ab, which
recognizes cells dying of apoptosis in a PC-inhibitable fashion
(8), induced much greater increases in C1q deposition on ACs
(Fig. 4A). In contrast, T15 AB neither recognized freshly iso-
lated healthy thymocytes nor enhanced C1q deposition on these
cells (Fig. 4A). Additionally, the IgM isotype control, which
displayed only limited binding interactions with ACs at late
stage of apoptosis (not shown), induced only minor differences
in C1q deposition (Fig. 4A). These studies document the capac-
ity of the T15 clonotypic anti-PC Ab to greatly enhance C1q
deposition on ACs, with levels of C1q on ACs directly corre-
lating with relative levels of bound T15 Ab (Fig. 4A).
FIGURE 2. Serum IgM reactivity of B6 and congenic S107.1-deficient
adult mice with PC and MDA Ags. For these studies, wells were coated
with PC-BSA, C-PS, Ox-LDL, MDA-LDL, or MDA-BSA and developed
with enzyme-conjugated anti-IgM Ab. Serum values for individual mice
were determined with depicted values means  SD (n  3). Sera were
obtained on day 16 from naive 12-wk-old mice, or after bleeds on day 16
following treatment with 25 106 ACs on days 0, 7, and 14. Levels of IgM
anti-MDA Abs were higher in naive B6.S107.1/ mice than in B6 mice
at 1/400 dilution (p  0.005, two-tailed t test).
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FIGURE 3. Preferential induction of PC- and
MDA-reactive Ig-secreting cells by apoptotic cell
treatment. A, Representative ELISPOT results com-
pare splenic IgM-secreting cells from a naive (top)
and AC-treated (bottom) adult C57BL/6 (B6) mice,
and (B) from congenic homozygotic S107.1-deficient
(B6.S107.1/) mice. These studies depict results
from triplicate wells coated with anti-IgM (total IgM-
secreting cells), PC-BSA (PC), pneumococcal C-PS,
MDA-BSA (MDA), and BSA (albumin) as the neg-
ative control. Each dot represents a distinct Ig-secret-
ing cell after addition of 100,000 (top rows) or 25,000
(bottom rows) splenocytes. Data are depicted for es-
timated rates of IgM-secreting (C and E) and IgG-
secreting cells (D and F) for mononuclear cells har-
vested from the spleens (C and D) and bone marrows
(E and F), with values per million cells presented.
Values for individual mice are depicted, with mean
values of four mice per group shown as a horizontal
bar. Results are representative of two independent
experiments.
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Natural Abs to PC and MDA recruit C1q to ACs
We next evaluated the properties of natural Abs in the preimmune
repertoire of naive mice, and found that naive sera from both B6
and B6.S107.1/ mice have IgM natural Abs that bind a subset of
apoptotic thymocytes (Fig. 4B). Moreover, compared with the
level of C1q that bound AC in the presence of Ig-deficient sera,
incubation with sera from naive B6 and B6.S107.1/ mice re-
sulted in much higher levels of C1q deposition, which was pri-
marily associated with the subset of ACs with bound IgM (Fig.
4B). Furthermore, compared with naive mice, sera from AC-
treated mice produced even greater increases in IgM binding of
ACs, and these levels were also directly proportional to concordant
increases in C1q binding to ACs (Fig. 4B). In general, despite the
above-described differences in the expressed apoptosis-associated
binding specificities, the overall levels of IgM anti-AC Ab and C1q
binding were similar in naive B6 and B6.S107.1/ mice, and there
were also comparable increases in the proportion of ACs with asso-
ciated IgM and C1q after incubation with sera from AC-treated mice
(Fig. 4B).
To assess the binding specificity of these anti-AC Abs, we
performed Ag inhibition studies. As shown in a representative
study (Fig. 4B), we found that incubation of AC-treated B6 sera
with PC-BSA resulted in inhibition of the levels of IgM
(15%) and C1q deposition (48%) on ACs, compared with
the AC-treated sera alone or after control incubation with BSA.
Similarly, incubation with MDA-BSA also inhibited (16%)
IgM and (47%) C1q deposition onto ACs (Fig. 4B). These
studies therefore confirm that in AC-treated wild-type B6 mice,
Ab recognition of ACs is dominated by anti-PC and MDA Abs,
which are responsible for marked increases in the levels of as-
sociated C1q when compared with incubation with Ig-deficient
sera. Similar levels of inhibition by PC-BSA and MDA-BSA
were also found with naive B6 sera (not shown). Notably, in-
cubation of AC-treated B6.S107.1/ sera with MDA-BSA
also greatly inhibited the deposition of IgM (30%) and C1q
(58%) on ACs. In contrast, incubation of this T15-deficient
B6.S107.1/ serum with PC-BSA did not affect binding of
IgM Ab to AC or C1q deposition (1%) (Fig. 4B), with similar
findings found with naive sera (not shown).
Taken together, these findings demonstrate that these anti-AC
responses are Ag specific and do not represent nonspecific polyclonal
responses. We also found that even though B6.S107.1/ mice
are deficient in anti-PC Abs, their expression of MDA-inhibitable
Abs is unimpaired, which is consistent with the above-described
direct-binding specificity studies. Moreover, the recognition of
particular neoepitopes on ACs was shown to be determined by VH
gene inheritance, as the absence of a single VHS107.1 germline
gene resulted in a shift of in vivo immune recognition away from
PC-related and toward MDA-related determinants. However, it ap-
peared that there are compensatory changes, as the anti-AC re-
sponses in S107.1-deficient mice have the same effector capabili-
ties for augmenting the deposition of C1q onto the membranes of
cells undergoing apoptotic death.
Natural Abs enhance AC phagocytosis by immature DCs
To evaluate whether these Ab responses can affect the innate im-
mune function of AC clearance, we adapted an earlier described
assay for quantifying the phagocytic capacity of bone marrow-
derived conventional CD11c immature DCs (4, 24, 25). In a rep-
resentative flow cytometry study, after incubation of immature
DCs (98% CD11bCD11c) with CFSE-labeled ACs (Fig. 5A
and data not shown), DCs are here discriminated based on their
larger size (i.e., forward light scatter), or based on CD11c staining
(Fig. 5B and data not shown). Importantly, this approach enables
identification of a distinct immature DC subpopulation that has
ingested CFSE-tagged ACs due to their associated shift in
fluorescence.
In control studies, under serum-free conditions (i.e., devoid of Ig
and opsonins) at 37°C the same low level of phagocytosis was
found for labeled healthy thymocytes (11.1 1.7%, n 3) as was
FIGURE 4. Deposition of C1q onto apoptotic thymocytes is primarily
mediated by anti-AC IgM Abs. A, Representative flow cytometric studies
demonstrate low but detectable levels of direct deposition of C1q from
Ig-deficient sera onto thymocytes undergoing etoposide-induced apoptosis
(i.e., ACs), but not to healthy freshly isolated thymocytes (i.e., healthy
cells). Apoptosis was confirmed by annexin V staining (not shown). In the
presence of T15 IgM, but not isotype control, there is a distinct AC subset
with high levels of bound IgM that has a proportionate high level of dep-
osition of C1q. Without Ig-deficient sera there is little or no reactivity with
the anti-C1q detection reagent, and the background for the detection signal
is demonstrated with an isotype control for the C1q detection in the pres-
ence of T15 IgM and sera (not shown). B, Top, Incubation of naive (left)
or AC-treated B6 sera (right) results in deposition on AC of IgM and
proportionate deposition of C1q primarily in the IgM-associated ACs.
While levels are higher with AC-treated B6 sera, IgM and also C1q binding
are reduced by preincubation with PC-BSA (PC) or MDA-BSA (MDA) but
not by BSA alone. Bottom, Incubation of naive (left) or AC-treated
B6.S107.1/ sera (right) also results in deposition on AC of IgM and
C1q, with higher levels of both associated with AC-treated sera. Here,
binding of IgM and C1q is reduced by preincubation with MDA-BSA but
not by PC-BSA or BSA alone. Results are representative of three inde-
pendent studies.
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FIGURE 5. T15 IgM binds apoptotic cells
and by recruitment of serum factors enhances
phagocytosis by conventional DCs. A, Flow cy-
tometric analysis of a representative study of pu-
rified bone marrow-derived conventional imma-
ture DCs after incubation with CFSE-labeled
apoptotic thymocytes. Healthy DCs are shown to
be larger (i.e., forward light scatter (FSC)), while
the smaller apoptotic thymocytes have been la-
beled with CFSE, which allows identification of
the subset of DCs that have ingested ACs. B,
Using this gating, representative results compare
outcome after incubation of DCs and ACs for 45
min at 37°C, without or with T15 IgM or isotype
control at 20 g/ml. C, Representative results
from cultures with 20% Ig-deficient sera and ad-
dition of IgM (T15, isotype control, or none) af-
ter 45 min at either 37°C or 4°C. Compared with
the limited level at 4°C, phagocytosis is greatly
up-regulated at 37°C, with greatest activity with
the highest level of T15 IgM and Ig-deficient
sera. D, Representative deconvoluted micros-
copy images (20) of cytospins of replicate cul-
tures with T15 IgM at 20 g/ml and Ig-deficient
sera after incubation at either 37°C (top) or 4°C
(bottom) for 45 min. A 10-m bar is indicated
for size comparisons. E, Flow cytometric deter-
mination of values for the percentage of imma-
ture DCs that have engulfed ACs are plotted
against values obtained from microscopic eval-
uation of 700 DCs per condition, from repli-
cate cultures after 45 min. Data were compliled
from percentage of DCs that have engulfed ACs
after 1 h at 37°C, with titrated T15 IgM concen-
trations. F, Addition of Ig-deficient sera results
in dose-dependent increases in phagocytosis,
with lower levels in the absence of Ig or in the
presence of the IgM isotype control after incu-
bation for 1 h at 37°C. Higher levels are associ-
ated with the T15 IgM at 20 g/ml. G, The ad-
dition of purified C1q results in dose-dependent
increases in phagocytosis, with much lower lev-
els in the absence of Ig, or presence of the IgM
isotype control, compared with higher levels
with the T15 IgM at 20 g/ml after incubation
for 1 h at 37°C. Results are representative of
three independent studies.
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documented for apoptotic thymocytes (11.6  0.9%, n  7) (Fig.
5F). Importantly, while the addition of 20% Ig-deficient sera sig-
nificantly increased the level of phagocytosis of ACs at 1 h at 37°C
(18.5  0.5%, p  0.0001, t test with Welsh correction, n  3),
compared with serum-free conditions, these conditions were not
associated with enhanced phagocytosis of CFSE-labeled healthy
thymocytes (not shown). These findings confirm the importance of
serum opsonins for enhancing the phagocytosis of cells undergo-
ing apoptotic death.
In studies that assessed the role of anti-AC Abs to DC phago-
cytosis, we found that in the absence of serum factors the addition
of T15 IgM resulted in only modest increases of DC phagocytosis
(mean 13.7  1.4%, n  7). Significantly, in the presence of Ig-
deficient sera the addition of T15 IgM resulted in significant se-
rum-dependent increases in the levels of AC engulfment (mean
36.1 3.3%, n 3) ( p 0.01) (Fig. 5F), as 20% Ig-deficient sera
and T15 IgM were associated with a 2.5-fold increase in phago-
cytosis compared with the absence of IgM, or with the IgM isotype
control (Fig. 5F). Importantly, engulfment was temperature-de-
pendent, as following incubation at 4°C with the T15 anti-PC
Ab and 20% Ig-deficient sera, we found only very few (3%)
DCs had ingested CFSE-tagged ACs as detected by flow cy-
tometry (Fig. 5B).
To better examine the actual interactions between DCs and
ACs that were detected in the flow cytometric studies, cytospins
of these same samples were visualized by deconvoluted micros-
copy (Figs. 5C–E). After incubation at 37°C, we found that
many DCs had ingested one or more labeled ACs or cell frag-
ments, while after incubation at 4°C labeled ACs were rarely
found fully within the DCs (Fig. 5D). Further documenting the
accuracy of this assay for quantifying DCs that engulf ACs, the
results from flow cytometric and digital confocal studies had
remarkably high positive correlation (r2  0.996, p  0.002;
Fig. 5E). Hence, this flow cytometry-based assay was therefore
shown to be highly quantitative for assessing the relative effi-
ciency for AC engulfment, and not just membrane association,
with conventional immature DCs.
C1q enhances natural Ab-mediated AC phagocytosis
We also looked for potential interactions of serum anti-AC Abs
with C1q, the recognition factor of the classical complement
pathway that has well-known roles in immune complex func-
tions. Compared with serum-free media, the addition of C1q to
serum-free media provided a dose-dependent increase in DC
phagocytosis, which reiterated overall patterns seen with the
addition of Ig-deficient sera. Moreover, the level of phagocy-
tosis after addition of C1q was similar whether incubated in the
presence of the IgM isotype control or without Ig (Fig. 5G).
Strikingly, the addition of T15 IgM further enhanced the ca-
pacity of DCs for AC phagocytosis, which was dependent on
the relative concentration of C1q. However, while C1q alone
enhanced T15 IgM-dependent increases in phagocytosis, there
were still much greater increases with Ig-deficient sera. These
findings suggest that C1q alone can convey natural Ab effector
functions required for enhanced DC phagocytosis, although the
full level of phagocytosis associated with Ig-deficient sera ap-
pears to involve additional factors.
Based on reports that myeloid cells can themselves produce
complement and likely other opsonic factors (39, 40), we repeated
studies of the same design with bone marrow-derived DCs made
from homozygotic C3-deficient congenic mice, but we found nei-
ther differences from wild-type DCs in the baseline level of phago-
cytosis without Abs or serum factors (i.e., only serum-free media)
(C3/, 10.9  0.1%, n  3 vs B6 11.6  0.9%, n  7, NS) nor
the levels attained with 10% Ig-deficient sera (15.1  0.7% n  3
vs 15.70.35%, n  3, NS) or with the addition of T15 IgM at 20
g/ml along with serum opsonins (29.4  2.9% vs 31.1  0.45%,
n  3, NS). These findings document that anti-AC Abs enhance
phagocytosis by a process that can be mediated by C1q alone, and
they also suggest that sera likely contain additional soluble factors,
other than C3, that can further enhance natural Ab-mediated DC
phagocytosis of ACs.
Oxidation-associated determinants inhibit natural Ab-dependent
phagocytosis
To better assess the potential physiologic relevance of these
findings, we next evaluated the effect on DC phagocytosis of
sera that vary in content of anti-AC Abs. As described above,
compared with the baseline activity levels associated with se-
rum-free media, phagocytosis was increased by addition of Ig-
deficient sera (Figs. 5E and 6, A and B), while addition of Ig-
containing sera from either naive B6 or B6.S107.1/ mice
resulted in even greater dose-dependent increases in DC phago-
cytosis of ACs ( p  0.01) (Fig. 6, A and B). In comparison,
addition of sera from AC-treated mice, which have much
greater concentrations of anti-AC, was associated with even
higher levels of DC phagocytosis (Fig. 6B). Hence, sera from
B6 and B6.S107.1/ mice conveyed a level of activity in an
AC phagocytosis assay that was directly proportional to the
associated IgM anti-AC binding activity (Figs. 4B and 6B).
As AC treatment increased Ab responses to PC and MDA
determinants (Figs. 1–3 and 4B), we evaluated the contribution
of such Abs to the efficiency of DC phagocytosis. In control
experiments, there was no reduction in DC phagocytosis levels
of ACs when 10% Ig-deficient sera were incubated with BSA or
MDA-BSA or PC-BSA conjugates (not shown). In contrast, in-
cubation of either PC-BSA or MDA-BSA conjugates with naive
B6 sera, which contains natural Abs, significantly inhibited DC
phagocytosis, causing 64% ( p  0.05) and 73% ( p  0.001)
reduction, respectively (Fig. 6C). Moreover, when MDA-BSA
was added together with PC-BSA to naive B6 sera, there was
greater inhibition than with either alone (i.e., 100% inhibition
of the Ig contribution) ( p  0.001), as DC phagocytosis was
reduced to the level associated with the same dilution of Ig-
deficient sera. Sera from AC-treated B6 mice, which conveyed
higher levels of phagocytosis, were also significantly inhibited
by either PC-BSA and MDA-BSA, representing 54% ( p 
0.05) and 57% inhibition ( p  0.05), respectively. Once again,
when PC-BSA and MDA-BSA were added together to AC-treated B6
sera, there was a greater inhibition (80.6%, p 0.01) than with either
conjugate alone, which suggested that the sera contains non-cross-
reacting Abs to MDA and PC determinants that separately enhance
phagocytosis (Fig. 6C).
Studies of sera from B6.S107.1/ mice reiterated the same
strain-specific patterns demonstrated in Ab-binding studies, as
there was no inhibition of DC phagocytosis by BSA alone or by
the PC-BSA conjugate (Figs. 2, 3, and 6C), as these mice have
defective anti-PC responses. In contrast, DC phagocytosis was
significantly inhibited by addition of MDA-BSA (65%, p 
0.01), while there was no significant difference in the level of
inhibition after the addition of PC-BSA and MDA-BSA to-
gether (74%) compared with MDA-BSA alone. Again, as levels
of anti-AC Abs were increased after AC treatment (Fig. 4B), we
confirmed our prediction that sera from AC-treated
B6.S107.1/ mice also conveyed higher levels of DC phago-
cytosis than sera from naive mice ( p  0.02) (Fig. 6). While
PC-BSA or BSA did not affect the level of phagocytosis asso-
ciated with sera from AC-treated B6.S107.1/ sera, MDA-
6038 IgM ANTIBODIES TO APOPTOTIC CELLS ENHANCE DC PHAGOCYTOSIS
 at Y
onsei M
edical Library on January 17, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
BSA did significantly inhibit DC phagocytosis of ACs (mean,
60.1%; p  0.01), but there was no further decrease by preincu-
bation of MDA-BSA together with PC-BSA (mean, 66.9%). Taken
together, these studies confirm the contributions of anti-AC Abs
and the dominance of PC- and MDA-related AC determinants to
the enhancement of the phagocytic function of immature DCs.
Strikingly, in the absence of the single VHS107.1 gene, PC-inhib-
itable determinants were no longer immunodominant and major
contributors to Ab-mediated DC phagocytosis, while the relative
contributions of MDA-inhibitable determinants on ACs were un-
affected or even increased.
Even though AC immunization induced an IgM response that
was much greater than the IgG response, we sought to evaluate
whether IgG Abs contributed to the Ig-dependent enhancement of
AC phagocytosis. For these studies, serum aliquots obtained after
AC treatment were passaged through a protein G-Sepharose col-
umn, which reduced IgG content by 96% without affecting IgM
activity (data not shown). After normalizing samples based on total
IgM concentration, we performed AC phagocytosis studies and
found no significant differences in the proportion of immature DCs
that had engulfed apoptotic thymocytes after 1 h in the presence of
IgG-depleted sera (protein G passaged (7.21  0.9%) vs untreated
(6.89  0.1%), NS, or vs control column passaged (7.89  0.6%),
n  3, NS). However, because different cellular ratios were used,
these specific values were not comparable to the above-described
studies. Importantly, these findings confirm that under these con-
ditions the IgM response to apoptosis-associated determinants is
the key determinant for the efficiency of serum-dependent DC
phagocytosis, and the minor AC-induced IgG response, of the
IgG3 subclass, is not a major contributor.
Discussion
The capacity to dispose of dead and dying cells is essential for the
host, and while a range of contributory molecules and pathways
has been characterized, the potential roles of host Ab responses in
these key processes have generally been overlooked. Herein, we
now demonstrate that naive mice have circulating natural Abs to
FIGURE 6. MDA- and PC-inhibitable Abs to apoptotic cells recruit C1q and enhance phagocytosis by DCs. A, Representative studies of IgM and C1q
binding to ACs after incubation with 10% sera from naive or AC-treated wild-type adult mice or mice deficient in the VHS107.1 gene (B6.S107.1/). The
percentage of DCs that ingested ACs is indicated, after incubation for 1 h at 37°C. B, Results from replicate immature DC cultures, after incubation for
1 h at 37°C, showed consistent direct correlations of the proportion of added sera with the resulting level of enhanced AC apoptosis in replicate cultures.
Such differences were consistently documented in comparisons of replicate cultures containing different proportions of sera. C, To determine the Ag
specificity of serum Abs that affect DC phagocytosis, sera were first preincubated with PC-BSA, MDA-BSA, or BSA at 50 g/ml for 1 h at 37°C before
addition to cultures for 1 h at 37°C. Bars represent mean values and SDs for triplicate cultures. Top horizontal line is the mean level after serum incubation
with BSA, while the bottom horizontal line is the mean level obtained with Ig-deficient sera (i.e., Ig-independent activity level). Results are representative
of three independent studies.
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ACs that can enhance the capacity of immature DCs to phagocy-
tose ACs, and this fundamental process can be further enhanced by
Ab responses induced by i.v. challenge with ACs. We also provide
the first evidence that genetic inheritance, in this case VH germline
gene usage, determines the dominance of the Ags recognized on
ACs. These findings were confirmed by Ag-specific inhibition of
Ab binding and the associated recruitment of C1q to ACs, as well
as by documenting Ag-specific inhibition of Ab-mediated en-
hancement of DC phagocytosis of ACs. Hence, in contrast to an
earlier report that T15 IgM instead inhibited phagocytic clearance
by elicited macrophages (7), our results document that the T15
IgM, as well as anti-AC natural Abs, can significantly enhance DC
phagocytosis of ACs by a process that is highly dependent on the
availability of serum factors. Taken together, our studies document
the potent functional contributions of Ab responses for determin-
ing the AC phagocytic capacity of immature DCs.
Earlier surveys demonstrated that AC immunizations of healthy
mice can induce Abs to a range of nuclear and membrane-associ-
ated self-Ags (117, 9, 10). As the relative contribution of distinct
binding specificities to the in vivo Ab recognition of ACs has been
uncertain, we used a highly multiplex Ag array in our investiga-
tions, and to our knowledge performed the most extensive surveys
performed to date. Our studies also provided the first quantification
of the frequency of Ag-reactive B cells in antiapoptotic thymocyte
responses. Hence, based on a range of direct-binding and Ag-in-
hibition studies, we showed that these responses in C57BL/6 mice
are highly dominated by immune recognition of AC membrane
oxidation-associated PC and MDA neodeterminants.
Remarkably, in AC-treated mice 35% of the splenic IgM-se-
creting cells recognized PC determinants and 20% recognized
MDA determinants (Fig. 3, A and C). Furthermore, based on the
capacity of PC and MDA ligands for additive inhibition, Ab re-
sponses to these determinants do not appear to be highly cross-
reactive. Hence, despite the complexity of molecules that are dis-
played on these cells, PC and MDA determinants appear to
dominate Ab responses to apoptotic thymocytes in B6 mice, as
together these represent more than half of the functional anti-AC B
cell responses to these dying cells (Fig. 3C). This antigenic dom-
inance does not appear to be specific for death induced by etopo-
side, as our control studies showed that MDA and PC determinants
are also prominent in the recognition of thymocytes dying from
exposure to gamma-irradiation or dexamethasone (data not
shown), similar to findings previously reported with porcine aortic
endothelial cells dying from dexamethasone exposure (8, 18) (data
not shown). The above-described findings therefore refute the no-
tion that natural Ab responses are always inherently polyreactive,
or that ACs are inherently “sticky”, and that Ab binding to AC is
nonspecific. Nonetheless, although PC and MDA are the major
neoantigens on dying thymocytes, other self or altered self-Ags
might be predominantly expressed during the death of other cell
types (reviewed in Ref. 41).
We also investigated the relationship between the immune rec-
ognition of ACs and B cells that express T15 clonally related Abs.
T15 clonotypic B-1 cells spontaneously arise and become highly
represented during the first week of life, even in mice raised under
germ-free conditions (42). Subsequently, T15 idiotypically related
Abs dominate immune responses to experimental and microbial
PC Ags, and they provide optimal protection from systemic pneu-
mococcal infection (43). In addition to the paired canonical
VHS107.1 and V22 L chain rearrangements used in the classical
T15 B-1 cell clone, there are also anti-PC Abs that are reported to
express VHS107.1 H chain rearrangements paired with a range of
other light chains (44–48). In contrast, structurally diverse anti-PC
Abs without restricted Ab gene usage are instead produced during
T cell-dependent responses to PC-protein conjugates (reviewed in
Ref. 49). Importantly, no matter what their Ab gene usage or pre-
sumed mature B cell subset of origin, in a previous report we found
that all tested anti-PC Abs could recognize ACs and discriminate
them from healthy cells (8).
To assess the importance of T15-related Abs for in vivo re-
sponses to AC neodeterminants, we used the VHS107.1-deficient
murine strain developed by Kenny and colleagues (17). The
present studies showed that sera from VHS107.1-deficient mice,
both naive and after AC treatment, contained Abs that recognize
ACs, with the capacity to enhance AC phagocytosis by immature
DCs to levels comparable with wild-type mice. Nonetheless, in
both the pre- and postexposure repertoires, mice without this single
inherited VH gene had a marked paucity of anti-PC Ig-secreting
cells and dramatically reduced levels of PC-reactive Abs. Hence,
our studies clearly demonstrated that the capacity for robust re-
sponses to PC determinants on ACs requires the S107.1 VH gene.
Our studies extend earlier reports that the S107.1 gene plays an
essential role in the recognition of PC determinants on microbial
pathogens (17), and we now demonstrate its unique and irreplace-
able role in the recognition of PC determinants on ACs. In fact, the
germline configuration of S107.1 is extremely well suited for bind-
ing of PC determinants, as many replacement mutations have been
shown to result in impaired PC binding, while none has been found
that improve it (50, 51). Consequently, we postulate that the germ-
line S107.1 gene sequence has been selected during immune evo-
lution for its relationship with this neo-self AC-binding specificity.
Significantly, in the absence of the VHS107.1 gene, we found a
concurrent and compensatory expansion of MDA-reactive Ig-se-
creting B cells, which highlights the importance of this parallel set
of anti-AC Ab-secreting cells and the Abs to ACs. Our findings
therefore document that even when the availability of inherited
gene elements limits the range of neoepitopes that can be recog-
nized, and there is a proportionate reduction in the diversity of
preimmune B cell precursors, there remains a biologic pressure to
maintain comparable overall levels of anti-AC B cells and IgM
Abs. We interpret these findings as evidence of an immunologic
drive based on homeostatic functions that requires the maintenance
of high levels of these “autoreactive” B cells to ACs.
Our studies also illustrate that not all B-1 cell natural Abs, even
among those that bind phospholipid-related Ags, can recognize
apoptotic thymocytes and facilitate their clearance. As an isotype
control IgM, we used a representative of another prototypic B-1
cell set (52, 53), which expresses the characteristic VH11 rear-
rangement and recognizes bromelain-treated red cells (19). While
such Abs have been postulated to mediate in vivo removal of se-
nescent red cells, we found that this IgM neither recognized phos-
phorylcholine Ags nor significantly bound apoptotic thymocytes or
affected their phagocytosis. Nonetheless, it remains possible that
such Abs, while they display little or no activity in our assays with
apoptotic thymocytes, might be active in other systems, perhaps
involving senescent red cells.
Complement factors have previously been implicated in the
pathways by which polyclonal IgM responses may affect the
phagocytic functions of macrophages. Notably, the capacity to in-
duce C3 deposition on ACs was found to directly correlate with the
efficiency of AC phagocytosis by macrophages (26, 54). In fact,
several reports have pointed to a central role of the receptors
CD11b/CD18 (i.e., complement receptor 3, CR3) and CD11c (i.e.,
CR4) for C3 breakdown products, such as iC3b and C3b, in AC
immune recognition and clearance, especially in DCs. However,
these studies have also been criticized for the predominant use of
artificial experimental Ags and blocking Abs (35, 55–58).
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There is also substantial evidence that C1q, independent of be-
ing an upstream initiator of C3 activation, plays important direct
roles in phagocyte recognition and engulfment of ACs (32–34, 59).
C1q deficiency results in significant defects in the clearance of
ACs by stimulated and by resting peritoneal macrophages (35)
and, importantly, mice deficient in C1q have increased numbers of
glomerular apoptotic bodies independent of C3 activation (35, 60,
61). However, these studies did not take into consideration the
potential contribution of natural Abs in the serum. To reconsider
this key issue of whether purified C1q can affect Ab-mediated
phagocytic clearance by immature DCs, we used a reductionistic
and highly quantitative in vitro phagocytosis assay with serum-free
media. Notably, C1q can be recruited to many, but not all, Ab-
containing immune complexes, but even IgM Abs differ widely in
their capacity to recruit complement (62). Our studies confirmed
that purified C1q, under serum-free and Ig-free conditions, is di-
rectly deposited onto the cell membranes of apoptotic but not
healthy thymocytes. However, we also demonstrated that T15 IgM
fostered much higher levels of C1q deposition and phagocytosis of
ACs, compared with the absence of Ig, or in the presence of the
isotype IgM control that did not bind ACs. Moreover, T15 IgM
displayed a dose-dependent deposition onto ACs of purified C1q,
or of C1q from serum. At physiologically relevant levels, C1q also
imparted dose-dependent enhancement of T15 IgM-mediated DC
phagocytosis (Fig. 5G). Notably, our in vitro assay also demon-
strated that C3 is not essential for the recognition and engulfment
of apoptotic thymocytes by conventional DCs, which is consistent
with a recent report (63).
Our studies therefore demonstrate that AC phagocytosis is greatly
enhanced by naturally arising Abs, as well as AC-induced Abs, by a
process that can be dependent on C1q recruitment. However, C1q at
physiologic concentrations, akin to levels found in sera, did not attain
the levels of apoptotic phagocytosis associated with the addition of
sera (64). It is possible that greater activity could be attained with
other C1q preparations or with the use of an anti-AC IgM with greater
C1q-binding activity. However, as there are many other known op-
sonic factors, we postulate that there are other eat me factors, in ad-
dition to C1q, that contribute to natural Ab-mediated enhancement of
DC phagocytosis. While we were surprised to discover detectable
levels of AC phagocytosis even in the absence of serum proteins, it is
possible that these ACs might have become opsonized during the
period in culture in the presence of serum, before their use in phago-
cytosis assays. Indeed, this background level of phagocytosis could
also be due to interactions with the opsonins that may be locally pro-
duced by DCs themselves, as phagocytes are reported to produce a
range of opsonic and bridging molecules, such as C1q, C3, and even
MBL, among others (39, 40, 65–67).
There is increasing evidence that Abs to ACs are also com-
monly found in humans and play roles in health and disease. In
fact, in our recently published serologic survey of adult sys-
temic lupus erythematosus patients, we found evidence that hu-
man anti-MDA responses were more prominent than anti-PC
responses (21). Our present findings suggest that the promi-
nence of anti-PC responses in mice might be caused by the
dominant role of S107.1-encoded Ig products, while the ab-
sence of a functionally equivalent human VH gene may explain
why there is a greater dominance of anti-MDA responses in the
human anti-AC repertoire. Moreover, our recent systemic lupus
erythematosus studies also included three relevant cases in
which higher IgM anti-MDA and/or anti-PC responses corre-
lated with protection of individuals, who were otherwise genet-
ically predisposed, from the development of clinically active
systemic lupus erythematosus (21).
These findings have led us to consider how anti-AC re-
sponses may be involved in autoimmune pathogenesis. It is
therefore intriguing that inflammatory conditions are reported
to be associated with reduced levels of such IgM Abs (68, 69).
Furthermore, the experimental regimen used herein, in which
infusion of autologous apoptotic mononuclear cells induced an
IgM anti-AC Ab response that enhances apoptotic clearance, is
essentially equivalent to that used in extracorporeal photophere-
sis, a Food and Drug Administration-approved treatment with
documented efficacy in diseases that include graft-vs-host dis-
ease and allograft rejection (70). Hence, our findings suggest an
alternative mechanistic basis for benefits from extracorporeal
photopheresis, and they provide a rationale for further investi-
gations into how Abs to apoptosis-associated neodeterminants
can affect the pathogenesis of inflammatory and autoimmune
diseases. Additionally, Abs to PC and MDA bind to modified
LDL and atherosclerotic plaques (8). Hence, these natural Ab
responses may also affect the pathogenesis of atherosclerosis
(18, 71), a chronic inflammatory disease that is the most com-
mon cause of morbidity and mortality in Western society. Fur-
ther investigations are therefore required to assess the contri-
butions of natural anti-AC Abs, and perhaps DCs, to other
fundamental innate immune functions that may affect ho-
meostasis and the pathogenesis of inflammatory and autoim-
mune diseases.
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